Navigation Links
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Date:1/26/2009

SEATTLE, Jan. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that after communication with the Food and Drug Administration (FDA), CTI expects to begin submission of a rolling New Drug Application (NDA) and request priority review for pixantrone to treat relapsed aggressive non-Hodgkin's lymphoma (NHL) in the first quarter of 2009. If granted priority review a decision on the NDA could occur before the end of 2009.

"This communication from the FDA is a significant milestone for the Company and for patients with relapsed aggressive NHL as this could be the first drug approved for this unmet medical need," noted James A. Bianco, M.D. Chief Executive Officer of CTI. "With the potential for three drug approvals in 2009 we are on track to meet our objective of cash flow break even in the fourth quarter of this year."

The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI announced in November 2008 that it had achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778). Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increa
'/>"/>

SOURCE Cell Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
3. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
6. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
7. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
8. American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time
9. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
10. Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts
11. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014  MinuteClinic, the largest and fastest growing ... , has opened its first walk-in clinics in the ... in Corpus Christi and Portland ... Christi in December. The clinics are part ... in 2014. With the Corpus Christi -area openings, ...
(Date:10/2/2014)... Ireland , Oct. 2, 2014   West ... a global leader in innovative solutions for injectable drug ... manufacturing operations to include a new site in ... produce packaging components for insulin injector cartridges and other ... from pharmaceutical and biotech customers. Once operational, this new ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 2First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... CORAL SPRINGS, Fla., Jan. 27, 2011 Boca ... and Drug Administration (FDA) approval and commercial launch ... 10mg/300mg) Boca,s generic version of Victory Pharma,s Xodol®. ... relief of moderate to moderately severe pain ...
... Inc. (OTC Bulletin Board: LTUSD) ("Lotus" or the "Company"), ... and drugs in the People,s Republic of China ("PRC"), ... the Company has obtained land price guidance from the ... provide additional details regarding its 2008 purchase of land ...
Cached Medicine Technology:Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government 2
(Date:10/2/2014)... 2014 Recently, BambooIndustry.com, a professional company ... collection of bamboo floors . What’s more, the ... of its products at the moment. According to the ... 26 percent off. The promotion will be valid until ... http://www.bambooindustry.com ) are all made by qualified workers. A ...
(Date:10/2/2014)... October 02, 2014 BamboofloorChina.com is a ... products have won great appreciation from the global customers ... working hard to make more excellent items. All its ... to help all clients. , The company has ... to its website. Furthermore, the company’s marketing specialist ...
(Date:10/2/2014)... Oct. 1, 2014 (HealthDay News) -- Children with autism ... they,re fully capable of being more active, a small ... levels of 29 children, some with autism and some ... day of moderate physical activity and 70 more minutes ... 17 children with autism scored lower on strength, but ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... research study published today in the Journal of ... older than 50 years with moderate or severe chronic ... Researchers from the University of Melbourne randomly assigned 282 ... to no acupuncture or sham or pretend laser treatment. ... participants and acupuncturists blinded to laser and sham (inactive) ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2
... , CHARLESTON, W.Va., Dec. 4 UniCare ... and West Virginia Radio Corporation will be holding the ... Mission. Several local celebrities, including 2006 World,s Strongest Man ... State Natalie Tenant, and Governor and Mrs. Manchin will ...
... ... an information technology (IT) and web products and services provider for ... -hospital web sites earned ten awards in the Strategic Communications ... Solutions Executive Director of web products and services, Chris Catallo, at ...
... been made over the last 15 years in the healthcare ... Yet this progress in epilepsy management has not reached ... many of the nearly three million people in the United ... Schachter, M.D., president of the American Epilepsy Society (AES), there ...
... first indication they understand what 2-D images represent, researchers ... can recognize photographs of other monkeys they know, proving ... figure out if they,ve seen them before, researchers report. ... decipher the two-dimensional nature of a photograph, the scientists ...
... LOS ANGELES, Dec. 4 Yogen Fruz , the world,s ... themed "NUmixes" -- Yog-Nog and Mint Chocolate Chip ... at Yogen Fruz stores across North America. Yogen Fruz,s low-calorie Yog-Nog ... alternative to indulge in this holiday season. , "We ...
... ... of novel and effective computational methods for drug discovery, has joined ... developing rare chemical trading platform and builds database of commercially available ... chemists at InhibOx where they incorporate it into the virtual screening ...
Cached Medicine News:Health News:UniCare, Walmart Organize Circle of Hope To Help Mountain Mission Meet Increased Demand for Assistance 2Health News:CareTech Solutions Web Clients Earn Top Recognition in the Tenth Annual eHealthcare Leadership Awards Competition 2Health News:CareTech Solutions Web Clients Earn Top Recognition in the Tenth Annual eHealthcare Leadership Awards Competition 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 4Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: